Cantor Fitzgerald Weighs in on Annexon FY2025 Earnings

Annexon, Inc. (NASDAQ:ANNX) – Investment analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of Annexon in a report issued on Tuesday, January 21st. Cantor Fitzgerald analyst P. Stavropoulos forecasts that the company will post earnings per share of ($0.99) for the year. Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for Annexon’s current full-year earnings is ($0.96) per share.

A number of other research analysts have also recently weighed in on ANNX. Needham & Company LLC reiterated a “buy” rating and issued a $16.00 target price on shares of Annexon in a research note on Friday, November 15th. HC Wainwright reaffirmed a “buy” rating and set a $30.00 price target on shares of Annexon in a research report on Tuesday, December 17th. Six research analysts have rated the stock with a buy rating, According to MarketBeat, Annexon has an average rating of “Buy” and a consensus target price of $15.80.

Annexon Stock Down 0.7 %

Shares of NASDAQ ANNX opened at $4.17 on Wednesday. The company has a market capitalization of $444.50 million, a PE ratio of -3.97 and a beta of 1.11. Annexon has a twelve month low of $3.86 and a twelve month high of $8.40. The stock’s 50 day moving average price is $5.13 and its 200-day moving average price is $5.93.

Hedge Funds Weigh In On Annexon

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ANNX. Parkman Healthcare Partners LLC boosted its position in Annexon by 0.5% during the third quarter. Parkman Healthcare Partners LLC now owns 328,613 shares of the company’s stock valued at $1,945,000 after buying an additional 1,768 shares during the period. The Manufacturers Life Insurance Company lifted its holdings in Annexon by 1.6% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 159,586 shares of the company’s stock worth $945,000 after buying an additional 2,450 shares during the period. GSA Capital Partners LLP lifted its stake in Annexon by 10.7% in the third quarter. GSA Capital Partners LLP now owns 34,581 shares of the company’s stock worth $205,000 after acquiring an additional 3,355 shares during the period. MetLife Investment Management LLC boosted its holdings in Annexon by 11.8% in the third quarter. MetLife Investment Management LLC now owns 55,212 shares of the company’s stock valued at $327,000 after acquiring an additional 5,814 shares in the last quarter. Finally, Creative Planning increased its position in Annexon by 29.5% during the 3rd quarter. Creative Planning now owns 34,779 shares of the company’s stock valued at $206,000 after purchasing an additional 7,914 shares during the period.

About Annexon

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.